Optomed Valuation Multiples

Optomed Overview

About Optomed

Optomed PLC is a Finnish medical technology company and a manufacturer of handheld fundus cameras and screening software. The company provides AI-based screening solutions to support diagnostic processes and early detection. It develops retinal imaging technology that is patented, clinically validated, and has approvals in all key markets, including CE, FDA and NMPA. The company's products are sold via various sales channels in over 60 countries. It has two reportable segments: Devices and Software. The majority of revenue is derived from the Software segment, which offers products for optimal management of various screening operations as well as IT solutions and services for storing, viewing and working with medical images. Geographically, it generates maximum revenue from Finland.

Founded

2004

HQ

Employees

115

Website

optomed.com

Sectors

Medical DevicesBioTechLongevity

Financials (LTM)

Revenue: $21M

EBITDA: ($3M)

EV

$55M

Valuation Multiples

Multiples.vc

Start free trial

Optomed Financials

Optomed reported last 12-month revenue of $21M and negative EBITDA of ($3M).

In the same LTM period, Optomed generated $13M in gross profit, ($3M) in EBITDA losses, and had net loss of ($7M).

Optomed P&L

In the most recent fiscal year, Optomed reported revenue of $20M and EBITDA of ($4M).

Optomed expects next 12-month revenue of XXX and NTM EBITDA of XXX

Optomed Stock Performance

Optomed has current market cap of $64M, and enterprise value of $55M.

Optomed's stock price is $2.96.

Optomed Valuation Multiples

Optomed trades at 2.6x EV/Revenue multiple, and (16.1x) EV/EBITDA.

Optomed Financial Valuation Multiples

As of April 20, 2026, Optomed has market cap of $64M and EV of $55M.

Equity research analysts estimate Optomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Optomed has a P/E ratio of (8.8x).

Optomed Margins & Growth Rates

Optomed's revenue in the last 12 month grew by 15%.

Optomed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Optomed's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Optomed's rule of X is 23% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Optomed Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Optomed M&A Activity

Optomed acquired XXX companies to date.

Last acquisition by Optomed was on XXXXXXXX, XXXXX. Optomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Optomed Investment Activity

Optomed invested in XXX companies to date.

Optomed made its latest investment on XXXXXXXX, XXXXX. Optomed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).